STA
XLRN

Summit Trail Advisors’s Acceleron Pharma XLRN Stock Holding History

Summit Trail Advisors’s Portfolio XLRN Stock Details XLRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-26
Closed -$1K – 1877
2017
Q4 		$1K Buy
+26
New +$975 ﹤0.01% 1915

Other funds holding XLRN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

Summit Trail Advisors's XLRN Position: Q1 2018 in Review

Summit Trail Advisors sold out of Acceleron Pharma (XLRN) in Q1 2018, closing a stake of 26 shares — an estimated $1K sold.

Summit Trail Advisors first reported a position in XLRN in Q4 2017 and held it in 1 quarter. The position peaked at $1K in Q4 2017. 150 funds tracked by Wall St. Rank hold XLRN as of Q1 2018.

  • Summit Trail Advisors reported no remaining Acceleron Pharma position as of Q1 2018 after selling out during the quarter.
  • Summit Trail Advisors sold 26 Acceleron Pharma shares in Q1 2018, an estimated $1K.
  • Summit Trail Advisors first reported a position in Acceleron Pharma in Q4 2017 and held it in 1 quarter.
  • Summit Trail Advisors's Acceleron Pharma position peaked at $1K in Q4 2017.
  • 150 funds tracked by Wall St. Rank held Acceleron Pharma as of Q1 2018.

Based on Summit Trail Advisors's 13F filing for Q1 2018, filed 21 May 2018.